Bryce Peek, OD
Optometrist · Barboursville, WVNPI 1881268563
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,174 of the $8,375 with a category attached, or 85.7%. 21 manufacturers reported payments, led by Alcon at 35.6% of the total. Reporting peaked in 2022 at $3,335 and has fallen 59.5% since, to $1,351 in 2025. Among optometrist clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $36.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Bausch & Lomb Americas Inc.$2K
- Sun Pharmaceutical Industries Inc.$791
- AbbVie$364
- Bausch & Lomb, A Division Of Bausch Health US, LLC$316
- Johnson & Johnson Vision Care, Inc.$236
- plus $2K from 15 others
What the payments were for
- Travel & lodging$1,20114%
- Food & beverage$7,17486%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 38 | $2,978 |
| Bausch & Lomb Americas Inc. | 78 | $2,119 |
| Sun Pharmaceutical Industries Inc. | 37 | $791 |
| AbbVie | 13 | $364 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $316 |
| Johnson & Johnson Vision Care, Inc. | 11 | $236 |
| Tarsus Pharmaceuticals, Inc. | 12 | $222 |
| AstraZeneca | 2 | $201 |
| Dompe US, Inc. | 5 | $178 |
| Oyster Point Pharma, Inc. | 8 | $176 |
| Eyevance Pharmaceuticals LLC | 3 | $162 |
| LKC Technologies, Inc. | 2 | $132 |
| Amgen | 1 | $124 |
| Lombart Brothers, Inc. | 1 | $119 |
| Apellis Pharmaceuticals, Inc. | 1 | $90 |
| Novartis | 3 | $59 |
| Biotissue Holdings Inc. | 2 | $43 |
| Harrow Eye, LLC | 1 | $22 |
| Thea Pharma Inc. | 1 | $16 |
| Kala Pharmaceuticals, Inc. | 1 | $14 |
| Spark Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIR OPTIX$1,494
- DAILIES TOTAL1 Multifocal$1,494
- Dailies Aqua Comfort Plus$1,494
- INFUSE$954
- Clareon$227
- TOTAL30$139
- DAILIES TOTAL1$137
- Tobradex ST$133
- MIEBO$125
- XIIDRA$125
- CEQUA$125
- UPLIZNA$124
- OPD-III$119
- Precision 1$111
- Oxervate$107
- AcrySof IQ PanOptix UV IOL$102
- AcrySof IQ VIVITY$102
How this compares
$8,375 in reported general payments places this provider in the 95th percentile of 210 optometrist providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 53 | $68,276 |
| LumiganBimatoprost | 24 | $13,933 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $5,295 |
| Latanoprost | 62 | $1,064 |
| Prednisolone Acetate | 19 | $979 |
| Brimonidine Tartrate | 23 | $606 |
| Timolol Maleate | 13 | $276 |
| Dorzolamide Hcl | 19 | $270 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 19 | $236 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 16 | $204 |
| ErythromycinErythromycin Base | 11 | $122 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $95 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $364 | $87,50490 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 210 optometrist providers in West Virginia.
Other optometrist in Barboursville
- Kayla CampbellBarboursville$16K
- Melissa LeoniBarboursville$6K
- Gregory MooreBuckhannon$28K
- Steven PotwinSaint Albans$24K
- Lee MooreCharles Town$10K
- Jill ShowalterVienna$10K
- James FickClarksburg$8K
- Laura Suppa SammonsCharleston$8K
- Mark WhittingtonCharleston$8K
- Hobart SeeseMorgantown$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.